Healthcare Industry News: Cytogen
News Release - February 28, 2006
Fredrick D. Cobb Appointed Vice President of Finance at AdvaxisNORTH BRUNSWICK, N.J.--(HSMN NewsFeed)--Feb. 28, 2006--Advaxis, Inc. (OTCBB: ADXS ), a developer of Listeria based cancer vaccines, has added to its management team Fredrick D. Cobb as VP of Finance. Mr. Cobb is an accomplished financial professional with a 30-year record of successfully managing corporate finance, operations, and accounting within the biotechnology and Fortune 100 pharmaceutical sectors. His career includes high management positions with Bristol-Myers Squibb, Emisphere Technologies Inc, and most recently with Metaphore Pharmaceuticals. He possesses both knowledge of and experience working with US GAAP requirements, SEC reporting, and Sarbanes-Oxley Act implementation. He has also liaised with external auditors and prepared initial public offering documentation for companies involved in the development and commercialization of new chemical entities.
Roni Appel, Chief Executive Officer of Advaxis, commented: "As our company advances, it has become necessary to hire highly qualified staff on the finance and administrative sides. Bringing Fred Cobb to our company makes us much stronger on many levels. His experience and success working on the financial end of large and small biotech companies will help ensure that our Company's financial needs are met and our company continues to grow at the appropriate pace."
Mr. Cobb holds a BS degree in Business Management from Cornell University and a Masters Degree in Accounting from Seton Hall University.
Based in North Brunswick, New Jersey. Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monoCytogenes based system, which utilizes two immunological mechanisms (Innate and Classical Immunity) to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis is entering a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.